Catalyst
Slingshot members are tracking this event:
Phase 3 data of Betrixaban (The APEX Study) for the prevention of Venous thromboembolism (VTE) by late 1Q 2016
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
PTLA |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 24, 2016
Occurred Source:
http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsroomArticle&ID=2150685
Related Projects
- Diving into Portola's strategy laid out in the NEJM for obtaining FDA approval of Betrixaban in preventing VTE in Acute Medically Ill patients after APEX failed. PTLA Executed On: Feb 14, 2017 at 12:00 PM EST
- Preparing for the APEX study data read out of betrixaban, expected in the end of q1 2016. Specifically discussing the bleeding rate bogey the drug needs to hit in relation to Enoxaparin PTLA, NVS, MNTA, SNY Executed On: Feb 05, 2016 at 05:00 PM EST
Related Keywords
Betrixaban, Phase 3, Apex, Venous Thromboembolism, Vte, Thromboembolism, Venous Thrombosis